TriReme Medical, Inc.

2013/3/27 10:35


AsiaNet 52541

共同JBN 0334 (2013.3.27)

【プレザントン(米カリフォルニア州)、シンガポール2013年3月26日PRN=共同JBN】TriReme Medical, Inc.とその子会社(TriReme)は26日、中国山東省の威海威高集団医用高分子製品有限公司(Weihai Weigao Medical Devices, Ltd.)と製品を販売する包括的協定を結んだと発表した。威高はTriReme製品を病院に直販するとともに、全国的な販売ネットワークにTriReme製品を乗せることによって、TriRemeの主たる販売業者として活動する。この協定はインターベンショナル心臓内科で最速成長しているアジアを重視するTriRemeの戦略を補完するものである。


シンガポールのEDBI(EDB Investments)およびBio*One Capitalのチュー・スウィーヨックCEO兼社長は「われわれはTriRemeの製品と技術が中国の患者により優れた医療成果をもたらすと確信しており、世界最速で成長中のヘルスケア市場にTriReme製品を持ち込むため威高集団のような優れたプレーヤーと提携することに興奮している。そのような提携関係は、TriRemeのような極めて革新的な企業が、成長を目指す重要なアジア市場にアクセスする基盤としてシンガポールを活用する極めて貴重な実例である」と語った。


▽TriReme Medical, Inc.について

米カリフォルニア州プレザントンとシンガポールに本社を置くTriReme Medical, Inc.は株式非公開の医療機器会社で、複雑な冠動脈、末梢動脈疾患を治療する次世代の経皮機器の開発、製造、商業化に専念している。同社は米国と新興アジア市場に注力している。



ソース:TriReme Medical, Inc.


Gail Prince,

+1-925-931-1300 ext 208

TriReme Announces Signing of a Master Distribution Agreement in China


PLEASANTON, Calif. and SINGAPORE, March 26, 2013 /PRN=KYODO JBN/ --

          -- Chinese Partner, Weigao, is One of Largest Medical Device

                        Players in the Middle Kingdom

    TriReme Medical, Inc. and its affiliates (TriReme) announced today that it

has signed a comprehensive agreement with Weihai Weigao Medical Devices, Ltd

for the distribution of its products in the People's Republic of China. Weigao

will act as TriReme's master distributor by selling TriReme products directly

to hospitals as well as connecting TriReme products into its vast nationwide

distribution network. This agreement complements TriReme's strategy of focusing

on Asia, the fastest growing market in interventional cardiology.

    "Due to many factors including increased affordability, aging population

and an increase in the number of state-of-the-art medical facilities, China has

become the world's second largest market in terms of the volume of

interventional coronary vascular procedures," stated Eitan Konstantino Ph.D,

CEO and President of TriReme. "For similar reasons, we expect that the number

of peripheral vascular procedures will rise dramatically in the coming years to

the point where China becomes the world's largest market in terms of total

vascular interventions."

    Ms CHU Swee Yeok, CEO and President, EDBI and Bio*One Capital said: "We are

confident that TriReme products and technologies will lead to better clinical

outcomes for Chinese patients and are thrilled to partner with a distinguished

player like Weigao to introduce TriReme products into the world's fastest

growing healthcare market. Such a partnership is a great example of how highly

innovative companies like TriReme can leverage on Singapore as a base to access

vital Asia markets for their growth."

    "Weigao remains committed to partnering with healthcare providers across

China to provide access to best-in-class technology across a wide range of

product categories," explained Mr SUN Feng Wei, General Manager of Weigao

Medical Devices, Ltd. "We view TriReme as a top brand and this partnership

allows us to bring the highest quality devices to our growing customer base of

physicians performing interventional vascular procedures."

    About TriReme Medical, Inc.

    Based in Singapore and Pleasanton, California, TriReme Medical, Inc. is a

privately held medical device company dedicated to the development,

manufacturing, and commercialization of next generation percutaneous devices

for the treatment of complex coronary and peripheral arterial disease. The

company is focused on the US and the emerging Asian markets.

    About Weigao

    Based in Weihai, China and publicly traded on the Hong Kong Stock exchange

(Stock Code: 1066), Weigao manufactures and sells over 100 types of products,

including disposable medical consumables, orthopedic materials and tools,

medical needles, blood purification consumables, and interventional cardiology

devices. It maintains a vast distribution network of 24 regional sales offices,

30 customer service centers, 100 municipal representatives, and 1200 sales

representatives. It sells to over 2700 hospitals, 400 blood stations, and over

1500 distribution/trading partners across China.

    SOURCE: TriReme Medical, Inc.

    CONTACT: Gail Prince, +1-925-931-1300 ext 208